Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127270 · ClinicalTrials.gov registry record · Phase 4
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 395
- Enrollment target
NCT00127270: Completed Phase 4 study, sponsored by Novartis.
NCT00127270 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 395 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00127270, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 395 participants
- Enrollment target
Study Summary
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Interventions
- DRUG Darifenacin
- BEHAVIORAL Behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
What the finished NCT00127270 record still lists
NCT00127270 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which Darifenacin is the first listed.
NCT00127270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00127270 about?
NCT00127270 is a clinical study titled "Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder". This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
What is the current status of trial NCT00127270?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 395 participants. The study started on 2005-05. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00127270?
The interventions under investigation include: Darifenacin (DRUG), Behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00127270?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00127270's enrollment target sits among peer trials
395 218th of 2000 higher than 1,783 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia